前列腺癌术后不同分割模式放射治疗急性不良反应初步研究

doi:10.3760/cma.j.issn.1004-4221.2018.07.008

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的初步比较前列腺癌术后不同分割模式放疗不良反应。方法收集我院2011-2017年间接受前列腺癌术后中等分割(62.75 Gy分25次,2.51 Gy/次)和术后常规分割(72 Gy分36次,2 Gy/次)放疗患者资料。所有患者均接受了调强放射治疗(IMRT),每日图像引导放射治疗(IGRT)。采用倾向评分匹配法(PSM)将两组分别匹配35例,匹配因素包括年龄、照射范围、内分泌治疗、手术—放疗间隔时间、以及合并症(糖尿病、高血压)。不良反应评价采用北美放射肿瘤协作组(RTOG)急性不良反应评价标准。差异行Fisher′s精确概率法检验。结果 113例患者纳入分析,其中中等分割组41例,常规分割组72例。中位随访时间分别为5.6、45.0个月。中等分割与常规分割组2级急性胃肠、泌尿不良反应分别为7%与7%(P=1.000)、15%与17%(P=0.847)。PSM匹配后两组2级急性胃肠、泌尿不良反应分别为9%与11%(P=0.814)、14%与11%(P=0.670)。无≥3级急性胃肠、泌尿不良反应。结论初步结果显示前列腺癌术后中等分割与常规分割相比未增加患者急性胃肠、泌尿不良反应风险。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	秦尚彬
	高献书
	李洪振
	顾晓斌
	李晓颖
	亓昕
	任雪盈

关键词 ：前列腺肿瘤/术后放射疗法, 放射疗法, 中等分割, 放射疗法, 常规分割

Abstract： Objective To compare the toxicity between different dose fractionation regimens in postoperative radiotherapy for prostate cancer. Methods Patients with prostate cancer who received postoperative radiotherapy with moderate hypo-fractionation (62.75 Gy in 25 fractions, 2.51 Gy per fraction) or conventional fractionation (72 Gy in 36 fractions, 2 Gy per fractions) in our hospital from 2011 to 2017 were enrolled as subjects. All patients received intensity-modulated radiotherapy and daily cone-beam computed tomography image-guided radiotherapy. According to the propensity score matching (PSM) method, 35 patients treated with moderately hypo-fractionated radiotherapy were matched to 35 patients treated with conventionally fractionated radiotherapy based on age, irradiated volume, hormonal therapy, interval between surgery and radiotherapy, and comorbidities (diabetes and hypertension). Toxicity was evaluated according to Radiation Therapy Oncology Group criteria. Comparison was made by the Fisher′s exact probability test. Results One hundred and thirteen patients, consisting of forty-one in moderate hypo-fractionation group and seventy-two in conventional fractionation group, were enrolled as subjects. The median follow-up time in the two groups was 5.6 and 45.0 months, respectively. There were no significant differences in incidence rates of grade 2 acute gastrointestinal (GI) or genitourinary (GU) toxicity between the two groups (7% vs. 7%, P=1.000;15% vs. 17%, P=0.847). After PSM, there were still no significant differences in incidence rates of grade 2 acute GI or GU toxicity between the two groups (9% vs. 11%, P=0.814;14% vs. 11%, P=0.670). None of patients reported≥grade 3 GI or GU toxicity. Conclusions Preliminary results show that moderate hypo-fractionation, compared with conventional fractionation, does not increase the risk of acute GI or GU toxicity in patients undergoing postoperative radiotherapy for prostate cancer.

Key words： Prostate neoplasms/postoperative radiotherapy Radiotherapy,moderately hypo-fractionated Radiotherapy,conventionally fractionated

收稿日期: 2018-01-16

基金资助:首都临床特色应用研究 (Z141107002514160)

通讯作者: 高献书,Email:doctorgaoxs@126.com

引用本文:

秦尚彬,高献书,李洪振等. 前列腺癌术后不同分割模式放射治疗急性不良反应初步研究[J]. 中华放射肿瘤学杂志, 2018, 27(7): 665-668.

Qin Shangbin,Gao Xianshu,Li Hongzhen et al. A preliminary toxicity study of different dose fractionation regimens in postoperative radiotherapy for prostate cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(7): 665-668.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.07.008 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I7/665

[1] Arcangeli S,Strigari L,Gomellini S,et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer[J].Int J Radiat Oncol Biol Phys,2012,84(5):1172-1178.DOI:10.1016/j.ijrobp.2012.02.049.
[2] Pollack A,Walker G,Horwitz EM,et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer[J].J Clin Oncol,2013,31(31):3860-3868.DOI:10.1200/JCO.2013.51.1972.
[3] Dearnaley D,Syndikus I,Mossop H,et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer:5-year outcomes of the randomised,non-inferiority,phase 3 CHHiP trial[J].Lancet Oncol,2016,17(8):1047-1060.DOI:10.1016/S1470-2045(16)30102-4.
[4] Mohler JL,Kantoff PW,Armstrong AJ,et al. Prostate cancer,version 2.2014[J].J Natl Compr Canc Netw,2014,12(5):686-718.
[5] National Comprehensive Cancer N.NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer[J].Verson 2.2017,https://www.nccn.org/professionals/physician_gls/default.aspx-prostate.
[6] Lewis SL,Patel P,Song H,et al. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer[J].Int J Radiat Oncol Biol Phys,2016,94(3):605-611.DOI:10.1016/j.ijrobp.2015.11.025.
[7] Wong GW,Palazzi-Churas KL,Jarrard DF,et al. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy[J].Int J Radiat Oncol Biol Phys,2008,70(2):449-455.DOI:10.1016/j.ijrobp.2007.06.042.
[8] Gladwish A,Loblaw A,Cheung P,et al. Accelerated hypofractioned postoperative radiotherapy for prostate cancer:a prospective phase Ⅰ/Ⅱ study[J].Clin Oncol (R Coll Radiol),2015,27(3):145-152.DOI:10.1016/j.clon.2014.12.003.
[9] Massaccesi M,Cilla S,Deodato F,et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy:preliminary results of a phase Ⅱ trial[J].Anticancer Res,2013,33(6):2785-2789.
[10] Macchia G,Siepe G,Capocaccia I,et al. Hypofractionated Postoperative IMRT in Prostate Carcinoma:A Phase Ⅰ/Ⅱ Study[J].Anticancer Res,2017,37(10):5821-5828.DOI:10.21873/anticanres.12025.
[11] Cozzarini C,Fiorino C,Deantoni C,et al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy:a single-institution analysis of 1176 patients[J].Eur Urol,2014,66(6):1024-1030.DOI:10.1016/j.eururo.2014.06.012.
[12] Kruser TJ,Jarrard DF,Graf AK,et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence[J].Cancer,2011,117(12):2629-2636.DOI:10.1002/cncr.25824.
[13] Michalski JM,Lawton C,El Naqa I,et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer[J].Int J Radiat Oncol Biol Phys,2010,76(2):361-368.DOI:10.1016/j.ijrobp.2009.02.006.
[14] D′souza WD,Thames HD.Is the alpha/beta ratio for prostate cancer low?[J].Int J Radiat Oncol Biol Phys,2001,51(1):1-3.
[15] Brenner DJ,Martinez AA,Edmundson GK,et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio),similar to late-responding normal tissue[J].Int J Radiat Oncol Biol Phys,2002,52(1):6-13.
[16] Fersino S,Tebano U,Mazzola R,et al. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT):a mono-institutional report on feasibility and acute toxicity[J].Clin Genitourin Cancer,2017,15(4):e667-e673.DOI:10.1016/j.clgc.2017.01.025.